Anil Sharma, MD
Psychiatry · Inglewood, CANPI 1447328109
Payments from drug & device makers
Across 193 payments — averaging $4338.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$311K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$226K
- Avanir Pharmaceuticals, Inc.$66K
- Boehringer Ingelheim$51K
- AbbVie$46K
- Eisai Inc.$35K
- plus $102K from 14 others
Across 6 payments — averaging $18,444 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$60K
- GRT US Holding, Inc.$50K
What the payments were for
- Food & beverage$870100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 20 | $310,837 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $225,888 |
| Avanir Pharmaceuticals, Inc. | 14 | $65,987 |
| Boehringer Ingelheim | 5 | $51,484 |
| AbbVie | 13 | $46,049 |
| Eisai Inc. | 29 | $35,002 |
| Guerbet LLC | 4 | $33,095 |
| Boehringer Ingelheim International GmbH | 44 | $22,660 |
| Teva Pharmaceuticals USA, Inc. | 6 | $14,260 |
| Indivior Inc. | 10 | $9,271 |
| Mallinckrodt LLC | 2 | $7,127 |
| Genentech, Inc. | 3 | $6,981 |
| Alkermes, Inc. | 11 | $3,941 |
| F. Hoffmann-la Roche AG | 3 | $2,666 |
| Eli Lilly | 1 | $1,500 |
| Johnson & Johnson | 14 | $497 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| DJO, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$240
- INVEGA TRINZA$119
How this compares
$837,333 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 76 | $591,681 |
| Clozapine | 85 | $4,025 |
| Olanzapine OdtOlanzapine | 24 | $1,585 |
| Divalproex Sodium | 37 | $1,519 |
| Mirtazapine | 27 | $435 |
| Quetiapine Fumarate | 26 | $311 |
| Olanzapine | 18 | $220 |
| Losartan Potassium | 11 | $188 |
| Trazodone Hcl | 20 | $154 |
| Aripiprazole | 15 | $152 |
| Atorvastatin Calcium | 12 | $147 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Inglewood
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.